GENERAL SESSIONS │ 8:00 am – 11:45 am


8:00 am – 8:05 am
Announcements and Pretest
R.V. Paul Chan, MD, MSc, FACS

Pediatrics, Pediatric Surgery, Gene Therapy and Upcoming Technologies

Session Chairs: R.V. Paul Chan, MD, MSc, FACS; Darius M. Moshfeghi, MD; Hiroko Terasaki, MD, PhD
8:05 am – 8:12 am
New Therapy Approaches for Retinopathy of Prematurity
Darius M. Moshfeghi, MD
8:12 am – 8:19 am
Artificial Intelligence for ROP Screening
R.V. Paul Chan, MD, MSc, FACS
8:19 am – 8:26 am
Subretinal Chip Implant for Retinal Degeneration
Helmut Sachs, MD
8:26 am – 8:33 am
What is the Correct Anti-VEGF Dose for ROP?
Maria A. Martinez-Castellanos, MD
8:33 am – 8:40 am
Surgical Management of Sticklers Syndrome
Antonio Ciardella, MD
8:40 am – 8:47 am
Hiroko Terasaki, MD, PhD
8:47 am – 8:54 am
Gene Therapy for RPE65 Mutated Retinal Degenerations
Audina M. Berrocal, MD
8:54 am – 9:01 am
The Surgical Management of Familial Exudative Vitreoretinopathy
Sengul Ozdek, MD, FEBO
9:01 am – 9:08 am
Early Experience with AAV8-RPGR Gene Therapy for X-linked Retinitis Pigmentosa
Byron L. Lam, MD

Panel Discussion

9:15 am – 9:35 am
Surgical ROP/Pediatric Case Analysis
Moderator: R.V. Paul Chan, MD, MSc, FACS
Panelists: Antonio Ciardella, MD; Hiroko Terasaki, MD, PhD; Maria A. Martinez-Castellanos, MD; Sengul Ozdek, MD, FEBO; Darius M. Moshfeghi, MD


Session Chairs: Thomas A. Albini, MD; Sofia N. Androudi, MD, PhD
9:40 am – 9:43 am
Sofia N. Androudi, MD, PhD
9:43 am – 9:50 am
Serpiginous and Serpiginous-like Choroiditis
Arif Hayat Khan Pathan, MD, MBBS (DMC), MCPS, FCPS, FRCS, ICO
9:50 am – 9:57 am
Using OCTA to Monitor Uveitis
Sumit Sharma, MD
9:57 am – 10:04 am
Update on Systemic Treatments for Non-infectious Uveitis
Pauline T. Merrill, MD
10:04 am – 10:11 am
MUST Study Outcomes and Impact on Clinical Practice
Thomas A. Albini, MD
10:11 am – 10:18 am
The Risk of Increased Intraocular Pressure with Uveitis Therapies
Michael A. Singer, MD
10:18 am – 10:25 am
New Local Therapies for Uveitis
Dilraj S. Grewal, MD

Abstract Winners

10:25 am – 10:28 am
Suprachoroidal administration of CLS-TA: Clinical Trial Results Demonstrating Rapid and Sustained Resolution of Macular Edema in Uveitis Patients
Eduardo Uchiyama, MD
10:28 am – 10:31 am
Incidence and Outcomes of Non-Infectious Vitritis and Infectious Endophthalmitis after Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents
Andre Muralha, MD

Panel Discussion

10:31 am – 10:53 am
Moderator: Sofia N. Androudi, MD, PhD
Panelists: Thomas A. Albini, MD; Pauline T. Merrill, MD; Sumit Sharma, MD

First-time Presentations of Clinical Trials and Late Breakers

Session Chairs: Pravin U. Dugel, MD; Sundaram Natarajan, MD
10:55 am – 10:58 am
Pravin U. Dugel, MD
10:58 am – 11:05 am
Optimizing DME Treatment with Decreased Injection Frequency with Long-term Steroid Implants
Daniel Roth, MD
11:05 am – 11:12 am
One Year Results of a Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in patients with Polypoidal Choroidal Vasculopathy (ATLANTIC STUDY)
DJoão Pedro Marques, MD, Msc
11:12 am – 11:19 am
Technology and Artificial Intelligence in the Retina Landscape
Linda A. Lam, MD, MBA
11:19 am – 11:26 am
The Evidence Behind Extended Anti-VEGF Dosing in Neovascular Age-related Macular Degeneration: A 5 Trial Cross-comparison
Theodore Leng, MD, MS
11:26 am – 11:33 am
Ladder Trial of the Port Delivery System with Ranibizumab: Initial Study Results
Franco Recchia, MD

Abstract Winner

11:33 am – 11:36 am
Open Label Study to Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients with Newly Diagnosed Neovascular Age-related Macular Degeneration (nAMD)
Michael Stewart, MD
11:36 am – 11:39 am
Pravin U. Dugel, MD

Meeting Adjourns

11:39 am – 11:45 am
Closing Remarks and Adjournment